These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

416 related articles for article (PubMed ID: 32622260)

  • 1. Electro-clinical analysis of epilepsy patients with generalized seizures on adjunctive perampanel treatment.
    Montoya Gutiérrez FJ; Díaz Román M; Cerveró Albert D
    Epilepsy Res; 2020 Sep; 165():106378. PubMed ID: 32622260
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Perampanel: Does it have broad-spectrum potential?
    Potschka H; Trinka E
    Epilepsia; 2019 Mar; 60 Suppl 1():22-36. PubMed ID: 29953584
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjunctive perampanel in partial-onset seizures: Asia-Pacific, randomized phase III study.
    Nishida T; Lee SK; Inoue Y; Saeki K; Ishikawa K; Kaneko S
    Acta Neurol Scand; 2018 Apr; 137(4):392-399. PubMed ID: 29250772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of adjunctive perampanel 4 mg/d for the treatment of focal seizures: A pooled post hoc analysis of four randomized, double-blind, phase III studies.
    Steinhoff BJ; Patten A; Williams B; Malhotra M
    Epilepsia; 2020 Feb; 61(2):278-286. PubMed ID: 31944276
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PERPRISE: A prospective non-interventional study of PERampanel as only adjunctive treatment in patients with PRImary or SEcondarily generalized tonic-clonic seizures: First interim analysis.
    Steinhoff BJ; Goldmann T; Kockelmann E; Winter Y;
    Epilepsia Open; 2024 Jun; 9(3):926-939. PubMed ID: 38017663
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Perampanel as adjunctive therapy in highly refractory epilepsies: Real-world data from an Italian tertiary care epilepsy centre.
    Morano A; Fattouch J; Albini M; Casciato S; Fanella M; Basili LM; Viganò A; Manfredi M; Giallonardo AT; Di Bonaventura C
    J Neurol Sci; 2018 Jul; 390():67-74. PubMed ID: 29801910
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: a pooled analysis of three phase III studies.
    Steinhoff BJ; Ben-Menachem E; Ryvlin P; Shorvon S; Kramer L; Satlin A; Squillacote D; Yang H; Zhu J; Laurenza A
    Epilepsia; 2013 Aug; 54(8):1481-9. PubMed ID: 23663001
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Perampanel for tonic-clonic seizures in idiopathic generalized epilepsy A randomized trial.
    French JA; Krauss GL; Wechsler RT; Wang XF; DiVentura B; Brandt C; Trinka E; O'Brien TJ; Laurenza A; Patten A; Bibbiani F
    Neurology; 2015 Sep; 85(11):950-7. PubMed ID: 26296511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Retrospective study of perampanel efficacy and tolerability in myoclonic seizures.
    Gil-López FJ; Montoya J; Falip M; Aparicio J; López-González FJ; Toledano R; Gil-Nagel A; Molins A; García I; Serrano P; Domenech G; Torres F; Donaire A; Carreño M
    Acta Neurol Scand; 2018 Aug; 138(2):122-129. PubMed ID: 29573400
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Perampanel as monotherapy and adjunctive therapy for focal onset seizures, focal to bilateral tonic-clonic seizures and as adjunctive therapy of generalized onset tonic-clonic seizures.
    Tyrlikova I; Brazdil M; Rektor I; Tyrlik M
    Expert Rev Neurother; 2019 Jan; 19(1):5-16. PubMed ID: 30560703
    [No Abstract]   [Full Text] [Related]  

  • 11. Safety and efficacy of perampanel in children and adults with various epilepsy syndromes: A single-center postmarketing study.
    Singh K; Shah YD; Luciano D; Friedman D; Devinsky O; Kothare SV
    Epilepsy Behav; 2016 Aug; 61():41-45. PubMed ID: 27300147
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of perampanel in adolescent patients with drug-resistant partial seizures in three double-blind, placebo-controlled, phase III randomized clinical studies and a combined extension study.
    Rosenfeld W; Conry J; Lagae L; Rozentals G; Yang H; Fain R; Williams B; Kumar D; Zhu J; Laurenza A
    Eur J Paediatr Neurol; 2015 Jul; 19(4):435-45. PubMed ID: 25823975
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Safety of adjunctive Perampanel in a prospective, real-world, Phase IV study in Indian patients aged ≥12 years for Treatment of focal-onset Epilepsy: Study 508.
    Ravat S; Rohatgi A; Kulkarni R; Jabeen SA; Patil B; Dash A; Malhotra M
    Epilepsia Open; 2024 Jun; 9(3):940-950. PubMed ID: 38124551
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness and tolerability of perampanel in children and adolescents with refractory epilepsies-An Italian observational multicenter study.
    De Liso P; Vigevano F; Specchio N; De Palma L; Bonanni P; Osanni E; Coppola G; Parisi P; Grosso S; Verrotti A; Spalice A; Nicita F; Zamponi N; Siliquini S; Giordano L; Martelli P; Guerrini R; Rosati A; Ilvento L; Belcastro V; Striano P; Vari MS; Capovilla G; Beccaria F; Bruni O; Luchetti A; Gobbi G; Russo A; Pruna D; Tozzi AE; Cusmai R
    Epilepsy Res; 2016 Nov; 127():93-100. PubMed ID: 27568598
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of adjunctive perampanel in adolescent patients with epilepsy: Post hoc analysis of six randomized studies.
    Piña-Garza JE; Rosenfeld W; Saeki K; Villanueva V; Yoshinaga H; Patten A; Williams B; Malhotra M
    Epilepsy Behav; 2020 Mar; 104(Pt A):106876. PubMed ID: 31954998
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Perampanel: A Review in Drug-Resistant Epilepsy.
    Frampton JE
    Drugs; 2015 Sep; 75(14):1657-68. PubMed ID: 26370209
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Perampanel, a selective, noncompetitive α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist, as adjunctive therapy for refractory partial-onset seizures: interim results from phase III, extension study 307.
    Krauss GL; Perucca E; Ben-Menachem E; Kwan P; Shih JJ; Squillacote D; Yang H; Gee M; Zhu J; Laurenza A
    Epilepsia; 2013 Jan; 54(1):126-34. PubMed ID: 22905878
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical profiles associated with serum perampanel concentrations in children with refractory epilepsy.
    Ishikawa N; Tateishi Y; Tani H; Kobayashi Y; Kobayashi M
    Epilepsy Behav; 2019 May; 94():82-86. PubMed ID: 30897534
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and tolerability of perampanel as a first add-on therapy with different anti-seizure drugs.
    Santamarina E; Bertol V; Garayoa V; García-Gomara MJ; Garamendi-Ruiz I; Giner P; Aranzábal I; Piera A; Arcos C; Esteve P; Marinas A; García-Escrivá A; Viloria-Alebesque A; Loro FA; de Tienda AP; Olivan JA; Bonet M; Dávila-González P; Sivera R; Molins A; Sansa G; Roche JC; Martínez AB; Monteagudo S; Casadevall T
    Seizure; 2020 Dec; 83():48-56. PubMed ID: 33096456
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exploring the Evidence for Broad-Spectrum Effectiveness of Perampanel: A Systematic Review of Clinical Data in Generalised Seizures.
    Trinka E; Lattanzi S; Carpenter K; Corradetti T; Nucera B; Rinaldi F; Shankar R; Brigo F
    CNS Drugs; 2021 Aug; 35(8):821-837. PubMed ID: 34232492
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.